FIELD: medicine; oncology.
SUBSTANCE: method is ensured by introduction of human antigene CTLA-4 antibody in number 15 mg/kg, furthermore specified antibody contains heavy and light chain amino acid sequence CDR presented in SEQ ID NOs: 17 and 19, respectively.
EFFECT: induction of antitumor immune response.
6 cl, 2 tbl, 10 dwg, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| DOSAGE REGIMENS FOR ANTIBODIES AGAINST TIM-3 AND THEIR USE | 2018 |
|
RU2804775C2 |
| VERSIONS OF HUMANIZED IMMUNOMODULATORY MONOCLONAL ANTIBODIES | 2012 |
|
RU2604814C2 |
| PHARMACEUTICAL COMPOSITION FOR TREATMENT AND/OR PREVENTION OF CANCER | 2014 |
|
RU2678138C2 |
| IMMUNE ENHANCING AGENT FOR TREATING A MALIGNANT NEOPLASM WITH USING AN ALLERGIN-1 ANTAGONIST | 2016 |
|
RU2734777C2 |
| PROTEINS BINDING PROSTAGLANDIN E2 AND USING THEM | 2009 |
|
RU2559525C2 |
| THIENO[3,2-c]PYRIDINE DERIVATIVES AS KINASE INHIBITORS FOR USE IN CANCER TREATMENT | 2009 |
|
RU2480472C2 |
| MONOCLONAL ANTIBODIES FOR TUMOUR TREATMENT | 2009 |
|
RU2531758C2 |
| CANCER TREATMENT USING TARGETED ANTIBODIES IN VIVO | 2011 |
|
RU2642305C2 |
| BISPECIFIC ANTIBODY MOLECULES AND ANTIGEN TRANSFECTED T-CELLS, AND THEIR USE IN MEDICINE | 2013 |
|
RU2693264C2 |
| ANTIBODIES SPECIFIC TO CLAUDIN 6 (CLDN6) | 2010 |
|
RU2675997C2 |
